AnGes MG Inc.

18 articles about AnGes MG Inc.

• 

  BioSpace Global Roundup, Sept. 10

  9/10/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Emendo Biotherapeutics Raises $61 Million to Advance Next Generation Genome Editing Therapeutics

  1/15/2020

  Emendo Biotherapeutics announced a Series B investment totaling $61 million led by AnGes, Inc., a Japan-based biopharma, reflecting its strategic interest in partnering with Emendo on the development of specific indications.

• AnGes Terminates Phase III HGF Plasmid, Starts New Plan

  6/27/2016

• AnGes MG Inc. Starts Global Phase 3 Clinical Trials Of Collategene® For Critical Limb Ischemia

  10/6/2014

• AnGes MG Inc. Enters Into the Definitive Agreement With Mitsubishi Tanabe Pharma Corporation for Exclusive Marketing Rights of Collategene® in the United States

  10/24/2012

• Vical Incorporated and AnGes MG Inc. Sign Letter of Intent for Pandemic Influenza Program

  10/9/2008

• Vical Incorporated and AnGes MG Inc. Sign Letter of Intent for Pandemic Influenza Program

  10/8/2008

• Vical Incorporated Receives $1 Million Milestone Payment From AnGes MG Inc. for Angiogenesis Program

  7/22/2008

• AnGes MG Inc. Files NDA in Japan for Collategene Angiogenesis Product

  3/28/2008

• Vical Incorporated Receives Payment from AnGes MG Inc. for Allovectin-7(R) Phase 3 Pivotal Trial

  1/17/2008

• AnGes MG Inc. Submits BLA to Japanese Ministry of Health

  8/13/2007

• Vical Incorporated Licensee AnGes MG Inc. Announces Positive Results of Phase 3 Angiogenesis Trial in Japan

  6/18/2007

• AnGes MG Inc., Vical Incorporated To Start Phase III Clinical Trial Of Allovectin For Gene Therapy

  1/17/2007

• Vical Incorporated Announces News Release And Conference Call Schedule To Discuss Collaborative Agreement With AnGes MG Inc. For Allovectin-7(R)

  5/30/2006

• Vical Incorporated And AnGes MG Inc. Sign $100M Deal; To Collaborate On Allovectin-7(R) And Begin Phase 3 Pivotal Trial

  5/30/2006

• AnGes MG Inc. Announces Results Of Phase I Clinical Trial Of HGF Gene Medicine

  5/12/2006

• AnGes MG Inc. And Seikagaku To Dissolve Joint Development Agreement For NFkB Decoy-Oligo-Based Intraarticular Injection

  2/6/2006

• AnGes MG Inc. And FALCO Biosystems To Form Business Alliance In Gene Therapy Business

  11/30/2005